Table 1. Crude proportion, and crude and adjusted odds ratios for diagnosis through emergency presentation, by age group, sex, deprivation group, year of diagnosis and cancer diagnosis.

		Emergency Presentation		Odds ratio (95% CI)a
	All cases	Number	%	Crude	Adjusted
All Cases	749 645	232 281	31.0%	N/A	N/A
Age
25–34	8586	1659	19.3%	0.65 (0.62–0.69)	1.10 (1.00–1.21)
35–44	22 356	4481	20.0%	0.68 (0.66–0.70)	1.01 (0.95–1.07)
45–54	57 128	12 920	22.6%	0.79 (0.78–0.81)	0.94 (0.90–0.97)
55–64	140 074	33 741	24.1%	0.86 (0.85–0.87)	0.91 (0.89–0.93)
65–74	208 095	56 025	26.9%	Reference	Reference
75–84	218 951	77 723	35.5%	1.49 (1.47–1.51)	1.47 (1.45–1.50)
85+	94 455	45 732	48.4%	2.55 (2.51–2.59)	2.62 (2.56–2.69)
Sex
Men	428 155	126 300	29.5%	Reference	Reference
Women	321 490	105 981	33.0%	1.18 (1.16–1.19)	1.06 (1.04–1.08)
Deprivation group
1—Least deprived	138 269	36 255	26.2%	Reference	Reference
2	155 743	44 332	28.5%	1.12 (1.10–1.14)	1.09 (1.06–1.11)
3	157 940	48 256	30.6%	1.24 (1.22–1.26)	1.19 (1.16–1.22)
4	152 953	50 779	33.2%	1.40 (1.38–1.42)	1.33 (1.30–1.36)
5—Most deprived	144 740	52 659	36.4%	1.61 (1.58–1.64)	1.55 (1.51–1.59)
Year of diagnosis
2006	146 259	47 987	32.8%	Reference	Reference
2007	147 473	46 333	31.4%	0.94 (0.92–0.95)	0.93 (0.91–0.96)
2008	152 125	46 784	30.8%	0.91 (0.90–0.92)	0.91 (0.89–0.93)
2009	153 600	46 890	30.5%	0.90 (0.89–0.91)	0.90 (0.88–0.92)
2010	150 188	44 287	29.5%	0.86 (0.84–0.87)	0.87 (0.85–0.89)
Cancer diagnosis
Melanomab	45 561	967	2.1%	0.03 (0.03–0.04)	0.04 (0.04–0.04)
Oral	9801	491	5.0%	0.08 (0.08–0.09)	0.09 (0.08–0.10)
Thyroid	8254	460	5.6%	0.09 (0.09–0.10)	0.11 (0.10–0.13)
Oropharynx	6429	365	5.7%	0.10 (0.09–0.11)	0.12 (0.10–0.14)
Anal	3381	345	10.2%	0.18 (0.16–0.20)	0.19 (0.16–0.22)
Laryngeal	8283	833	10.1%	0.18 (0.17–0.19)	0.20 (0.18–0.22)
Soft tissue sarcoma	4839	635	13.1%	0.24 (0.22–0.26)	0.26 (0.23–0.29)
Rectal	54 076	8177	15.1%	0.29 (0.28–0.29)	0.30 (0.28–0.31)
Hodgkin lymphoma	4768	674	14.1%	0.26 (0.24–0.29)	0.31 (0.28–0.35)
Bladderb	42 234	7834	18.5%	0.36 (0.36–0.37)	0.34 (0.33–0.35)
Oesophagealb	32 470	7062	21.7%	0.44 (0.43–0.46)	0.45 (0.43–0.47)
CLL	11 892	2950	24.8%	0.53 (0.51–0.55)	0.53 (0.49–0.56)
Renalb	29 469	7733	26.2%	0.57 (0.55–0.59)	0.62 (0.60–0.65)
Non-Hodgkinb lymphoma	46 329	12 393	26.7%	0.58 (0.57–0.60)	0.64 (0.62–0.66)
Colon	97 880	30 777	31.4%	0.73 (0.72–0.75)	0.73 (0.71–0.75)
Stomachb	29 893	9913	33.2%	0.79 (0.77–0.82)	0.75 (0.73–0.78)
Multiple myelomab	18 272	6693	36.6%	0.93 (0.90–0.96)	0.96 (0.91–1.00)
Mesothelioma	10 116	3631	35.9%	0.90 (0.86–0.93)	0.96 (0.90–1.02)
Lungb	162 543	62 498	38.5%	Reference	Reference
CML	1702	656	38.5%	1.00 (0.91–1.11)	1.01 (0.88–1.17)
Pancreaticb	33 295	16 364	49.1%	1.55 (1.51–1.58)	1.56 (1.51–1.62)
Liver	14 732	7270	49.3%	1.56 (1.51–1.61)	1.60 (1.52–1.68)
Unknown primary	43 290	24 805	57.3%	2.15 (2.10–2.19)	2.00 (1.94–2.07)
AML	9611	5388	56.1%	2.04 (1.96–2.13)	2.15 (2.02–2.29)
Small intestine	3399	1863	54.8%	1.94 (1.81–2.08)	2.15 (1.95–2.38)
Brainb	16 710	11 175	66.9%	3.23 (3.12–3.34)	3.96 (3.77–4.17)
ALL	416	329	79.1%	6.05 (4.78–7.67)	7.19 (5.08–10.16)

Abbreviations: ALL=acute lymphoblastic leukaemia; AML=acute myeloid leukaemia; CI=confidence interval; CLL=chronic lymphocytic leukaemia; CML=chronic myeloid leukaemia; NA=not applicable.

^aP<0.0001 for all based on joint test of categorical variables. A modest amount of overdispersion was found resulting in an increase in the width of confidence intervals of 45%.

^bSee also Elliss-Brookes et al, 2012.